Analysts Predict 12% Gains Ahead For The Holdings of FYX
ETF Performance Analysis: The First Trust Small Cap Core AlphaDEX Fund ETF (FYX) has an implied analyst target price of $119.72, indicating a potential upside of 12.14% from its current trading price of $106.76.
Individual Stock Upside Potential: Notable underlying holdings like Arcutis Biotherapeutics (ARQT), Agios Pharmaceuticals (AGIO), and Rhythm Pharmaceuticals (RYTM) show significant upside potential, with target prices suggesting increases of 35.80%, 32.94%, and 27.96% respectively from their recent share prices.
Trade with 70% Backtested Accuracy
Analyst Views on RYTM
About RYTM
About the author
Three Stocks Set to Outperform the Market in 2026
- Alphabet Cloud Growth: Alphabet's cloud business had an annual revenue run rate of approximately $70 billion at the end of 2025, with a backlog growth exceeding 100% year-over-year to $240 billion in Q4, which is expected to significantly enhance the company's profitability in 2026 and solidify its leadership in the AI sector.
- BeOne Drug Development Progress: BeOne Medicines plans to announce Phase 3 study results for Brukinsa in combination with rituximab in the first half of 2026, and is expected to gain U.S. regulatory approval for sonrotoclax, further enhancing its competitiveness in the blood cancer treatment market.
- Rhythm Drug Approval Outlook: Rhythm Pharmaceuticals' Imcivree is anticipated to receive FDA approval for treating acquired hypothalamic obesity by March 20, 2026, which would significantly expand its market potential as this condition affects more patients than the combined total of its three existing indications.
- Multiple Clinical Trial Data Releases: Rhythm also plans to report top-line data from a Phase 3 study evaluating Imcivree in four other genetic diseases in Q1 2026 and disclose results from an exploratory Phase 2 study on Prader-Willi syndrome in the first half of the year, further boosting investor confidence.
Rhythm Pharmaceuticals Stock Soars with Significant Growth Potential
- Significant Market Potential: Rhythm Pharmaceuticals, with a market cap of only $6.8 billion, has seen its stock price soar over the past 12 months, surpassing both Alphabet and Nvidia, indicating strong market performance and growing investor interest.
- Notable Sales Growth: The company's sole approved drug, Imcivree, achieved sales of $194 million in 2025, reflecting a year-over-year increase of approximately 50%, highlighting the rapid growth in demand for treatments in the rare disease sector.
- Clinical Trial Advancements: Rhythm plans to advance its oral MC4R agonist, bivamelagon, into Phase 3 clinical testing in 2026, while also conducting Phase 1 testing for another MC4R agonist, RM-718, showcasing the diversity and potential of its R&D pipeline.
- FDA Approval Catalyst: The FDA is expected to make a decision on Imcivree's application for treating acquired hypothalamic obesity on March 20, 2026, which could significantly enhance Rhythm's market opportunities, impacting treatment options for approximately 20,000 patients in the U.S.
Rhythm Pharmaceuticals: A Hidden Growth Stock Soaring
- Significant Market Potential: Rhythm Pharmaceuticals has a market cap of $6.8 billion, and despite its relatively small size, its stock has outperformed both Alphabet and Nvidia over the past 12 months, indicating strong market performance and investor confidence.
- Notable Sales Growth: The company's sole approved drug, Imcivree, achieved sales of $194 million in 2025, reflecting a year-over-year increase of approximately 50%, highlighting the growing market demand in the rare genetic obesity treatment sector.
- Promising Clinical Trials: Rhythm expects to advance its oral MC4R agonist, bivamelagon, into Phase 3 clinical testing in 2026, alongside another candidate, RM-718, in Phase 1 testing, showcasing the diversity of its pipeline and potential for market expansion.
- FDA Approval Catalyst: The anticipated FDA approval for Imcivree in treating acquired hypothalamic obesity on March 20, 2026, could potentially benefit over 36,000 patients across the U.S., Europe, and Japan, significantly enhancing the company's market outlook and profitability prospects.
Rhythm Pharmaceuticals Reports $194M in 2025 IMCIVREE Sales
- Significant Sales Growth: Rhythm Pharmaceuticals anticipates approximately $194 million in net product revenues from global sales of IMCIVREE® in 2025, representing a 50% increase from 2024, indicating strong market demand in the rare neuroendocrine disease sector.
- Quarterly Performance Boost: The estimated sales for Q4 2025 are around $57 million, reflecting an 11% increase from Q3 2025, showcasing sustained demand and patient acceptance for IMCIVREE in both U.S. and international markets.
- FDA Approval Progress: The company plans to submit a supplemental NDA for IMCIVREE for acquired hypothalamic obesity to the FDA by March 20, 2026, which, if approved, will further expand its market reach and address patient needs.
- Clinical Trial Data Release: Topline data from a 12-patient Japanese cohort in the Phase 3 trial is expected to be announced in Q1 2026, providing crucial support for the global promotion of IMCIVREE.
Rhythm Pharma Hits the Right Note with Promising Early Results from PWS Trial
Stock Performance: Rhythm Pharmaceuticals Inc. (RYTM) shares rose 14.24% to $119.69 following positive preliminary results from its Phase 2 trial of setmelanotide for Prader-Willi syndrome (PWS).
Trial Results: In the ongoing 52-week trial, setmelanotide showed potential benefits, with 6 of 8 patients achieving BMI reductions at Month 3 and 3 of 5 patients at Month 6, alongside significant reductions in hyperphagia.
Future Plans: The company plans to advance setmelanotide into a Phase 3 registrational trial for PWS, contingent on the successful completion of the current Phase 2 trial.
Additional Research: Rhythm has initiated a Part D arm in a Phase 1 trial for MC4R agonist RM-718, aiming to enroll up to 20 PWS patients, with the first screening expected in December 2025.
Rhythm Pharma to Share Initial Phase 2 Results of Setmelanotide for Prader-Willi Syndrome Today
Upcoming Data Release: Rhythm Pharmaceuticals will present preliminary data from its Phase 2 trial of Setmelanotide for Prader-Willi syndrome on December 11, 2025, addressing a rare genetic disorder with limited treatment options.
Setmelanotide Overview: The drug, already approved for obesity treatment in certain genetic conditions, is also under review for acquired hypothalamic obesity, with an FDA decision expected on March 20, 2025.
Pipeline Development: Rhythm is advancing additional MC4R agonists, including Bivamelagon and RM-718, with ongoing trials and plans for a pivotal phase III trial for Bivamelagon in 2026.
Financial Performance: The company reported third-quarter 2025 net product revenue of $51.3 million, with strong growth in U.S. sales, and ended September 30 with $416.1 million in cash and investments, supporting its development programs.
Three Stocks Set to Outperform the Market in 2026
- Alphabet Cloud Growth: Alphabet's cloud business had an annual revenue run rate of approximately $70 billion at the end of 2025, with a backlog growth exceeding 100% year-over-year to $240 billion in Q4, which is expected to significantly enhance the company's profitability in 2026 and solidify its leadership in the AI sector.
- BeOne Drug Development Progress: BeOne Medicines plans to announce Phase 3 study results for Brukinsa in combination with rituximab in the first half of 2026, and is expected to gain U.S. regulatory approval for sonrotoclax, further enhancing its competitiveness in the blood cancer treatment market.
- Rhythm Drug Approval Outlook: Rhythm Pharmaceuticals' Imcivree is anticipated to receive FDA approval for treating acquired hypothalamic obesity by March 20, 2026, which would significantly expand its market potential as this condition affects more patients than the combined total of its three existing indications.
- Multiple Clinical Trial Data Releases: Rhythm also plans to report top-line data from a Phase 3 study evaluating Imcivree in four other genetic diseases in Q1 2026 and disclose results from an exploratory Phase 2 study on Prader-Willi syndrome in the first half of the year, further boosting investor confidence.
Rhythm Pharmaceuticals Stock Soars with Significant Growth Potential
- Significant Market Potential: Rhythm Pharmaceuticals, with a market cap of only $6.8 billion, has seen its stock price soar over the past 12 months, surpassing both Alphabet and Nvidia, indicating strong market performance and growing investor interest.
- Notable Sales Growth: The company's sole approved drug, Imcivree, achieved sales of $194 million in 2025, reflecting a year-over-year increase of approximately 50%, highlighting the rapid growth in demand for treatments in the rare disease sector.
- Clinical Trial Advancements: Rhythm plans to advance its oral MC4R agonist, bivamelagon, into Phase 3 clinical testing in 2026, while also conducting Phase 1 testing for another MC4R agonist, RM-718, showcasing the diversity and potential of its R&D pipeline.
- FDA Approval Catalyst: The FDA is expected to make a decision on Imcivree's application for treating acquired hypothalamic obesity on March 20, 2026, which could significantly enhance Rhythm's market opportunities, impacting treatment options for approximately 20,000 patients in the U.S.
Rhythm Pharmaceuticals: A Hidden Growth Stock Soaring
- Significant Market Potential: Rhythm Pharmaceuticals has a market cap of $6.8 billion, and despite its relatively small size, its stock has outperformed both Alphabet and Nvidia over the past 12 months, indicating strong market performance and investor confidence.
- Notable Sales Growth: The company's sole approved drug, Imcivree, achieved sales of $194 million in 2025, reflecting a year-over-year increase of approximately 50%, highlighting the growing market demand in the rare genetic obesity treatment sector.
- Promising Clinical Trials: Rhythm expects to advance its oral MC4R agonist, bivamelagon, into Phase 3 clinical testing in 2026, alongside another candidate, RM-718, in Phase 1 testing, showcasing the diversity of its pipeline and potential for market expansion.
- FDA Approval Catalyst: The anticipated FDA approval for Imcivree in treating acquired hypothalamic obesity on March 20, 2026, could potentially benefit over 36,000 patients across the U.S., Europe, and Japan, significantly enhancing the company's market outlook and profitability prospects.
Rhythm Pharmaceuticals Reports $194M in 2025 IMCIVREE Sales
- Significant Sales Growth: Rhythm Pharmaceuticals anticipates approximately $194 million in net product revenues from global sales of IMCIVREE® in 2025, representing a 50% increase from 2024, indicating strong market demand in the rare neuroendocrine disease sector.
- Quarterly Performance Boost: The estimated sales for Q4 2025 are around $57 million, reflecting an 11% increase from Q3 2025, showcasing sustained demand and patient acceptance for IMCIVREE in both U.S. and international markets.
- FDA Approval Progress: The company plans to submit a supplemental NDA for IMCIVREE for acquired hypothalamic obesity to the FDA by March 20, 2026, which, if approved, will further expand its market reach and address patient needs.
- Clinical Trial Data Release: Topline data from a 12-patient Japanese cohort in the Phase 3 trial is expected to be announced in Q1 2026, providing crucial support for the global promotion of IMCIVREE.
Rhythm Pharma Hits the Right Note with Promising Early Results from PWS Trial
Stock Performance: Rhythm Pharmaceuticals Inc. (RYTM) shares rose 14.24% to $119.69 following positive preliminary results from its Phase 2 trial of setmelanotide for Prader-Willi syndrome (PWS).
Trial Results: In the ongoing 52-week trial, setmelanotide showed potential benefits, with 6 of 8 patients achieving BMI reductions at Month 3 and 3 of 5 patients at Month 6, alongside significant reductions in hyperphagia.
Future Plans: The company plans to advance setmelanotide into a Phase 3 registrational trial for PWS, contingent on the successful completion of the current Phase 2 trial.
Additional Research: Rhythm has initiated a Part D arm in a Phase 1 trial for MC4R agonist RM-718, aiming to enroll up to 20 PWS patients, with the first screening expected in December 2025.
Rhythm Pharma to Share Initial Phase 2 Results of Setmelanotide for Prader-Willi Syndrome Today
Upcoming Data Release: Rhythm Pharmaceuticals will present preliminary data from its Phase 2 trial of Setmelanotide for Prader-Willi syndrome on December 11, 2025, addressing a rare genetic disorder with limited treatment options.
Setmelanotide Overview: The drug, already approved for obesity treatment in certain genetic conditions, is also under review for acquired hypothalamic obesity, with an FDA decision expected on March 20, 2025.
Pipeline Development: Rhythm is advancing additional MC4R agonists, including Bivamelagon and RM-718, with ongoing trials and plans for a pivotal phase III trial for Bivamelagon in 2026.
Financial Performance: The company reported third-quarter 2025 net product revenue of $51.3 million, with strong growth in U.S. sales, and ended September 30 with $416.1 million in cash and investments, supporting its development programs.
